Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to
netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%